

Entrez PubMed Overview Heip | FAQ Tutorial New/Noteworthy E-Utilities

PubMed Services
Journals Database
MeSH Database
Single Citation Matcher
Batch Citation Matcher
Clinical Queries
Special Queries
LinkOut
My NCBI (Cubby)

Related Resources
Order Documents
NI.M Catalog
NLM Galeway
TOXNET
Consumer Health
Clinical Alerts
ClinicalTriats.gov
PubMed Central

Antibody response to herpes simplex virus type 1 polypeptides and glycoproteins in primary and recurrent infection.

Mann DR, Hilty MD.

Sequential sera from a patient with primary Herpes Simplex Virus type I (HSV-1) encephalitis and a patient with HSV-1 recurrent oral lesions were collected. Sera were analyzed quantitatively by radioimmunoassay and qualitatively by electrophoresis and autoradiography of immune precipitates to determine the sequence of antibody production to specific radiolabeled HSV-1 polypeptide and glycoprotein antigens. The major antibody response in both primary and recurrent sera was against HSV-1 envelope antigens and the major capsid polypeptide. Sequential sera showed a significant correlation between neutralizing antibody titers and quantitative antibody to HSV-1 glycoproteins. Qualitative electrophoretic analysis of primary infection sera showed sequential appearance of antibodies to increasing numbers of HSV-1 polypeptides by the fourteenth day of infection. A corresponding qualitative antibody response to glycoproteins was not seen. Sequential sera obtained before, during, or after a recurrent lip lesion in another patient showed no significant quantitative or qualitative changes in antibodies to either HSV-1 glycoproteins or polypeptides.

Publication Types:

Case Reports

PMID: 6278389 [PubMed - indexed for MEDLINE]

Display Abstract Sho	w 20 Sort by	♥ Send to ♥
----------------------	--------------	-------------

Write to the Help Desk


NCB! | NLM | NIH

Department of Health & Human Services

Privacy Statement | Freedom of Information Act | Disclaimer

Jun 1 2005 06:58:50

Page 1 of 2



Entrez PubMed Overview Help | FAQ Tutorial New/Noteworthy E-Utilities

PubMed Services
Journals Database
MeSH Database
Single Citation Matcher
Batch Citation Matcher
Clinical Queries
Special Queries
LinkOut
My NCBI (Cubby)

Related Resources
Order Documents
NLM Catalog
NLM Gateway
TOXNET
Consumer Health
Clinical Alerts
ClinicalTrials.gov
PubMed Central


Protection against herpetic ocular disease by immunotherapy with monoclonal antibodies to herpes simplex virus glycoproteins.

Metcalf JF, Chatterjee S, Koga J, Whitley RJ.

Department of Microbiology and Immunology, University of South Alabama, Mobile 36688.

In this paper we describe the ability of monoclonal antibodies to prevent herpetic stromal or interstitial keratitis following corneal infection in an outbred mouse model. Monoclonal antibodies recognizing antigenic determinants on glycoproteins B, C, D, and E of herpes simplex virus type 1 were injected intraperitoneally into CF-1 outbred mice 24 or 48 h following inoculation of the cornea with the RE strain of herpes simplex virus type 1. Passive, postexposure immunization with monoclonal antibodies had little effect on the severity of the initial corneal infection or the frequency of latent viral infections in the trigeminal ganglia, except for virus-neutralizing antibodies specific for glycoproteins B and D. A significant correlation was found between the severity of epithelial keratitis and the frequency of latent ganglionic infections. However, immunization with monoclonal antibodies protected the mice against encephalitis and prevented the development of necrotizing stromal keratitis that leads to permanent corneal scarring and blindness. This form of herpetic ocular disease does not respond to antiviral chemotherapy. Since nonneutralizing monoclonal antibodies were just as effective in prevention of encephalitis and stromal keratitis as ones that neutralized the virus in vitro, and antibodies were not administered until 24 or 48 h after corneal inoculation, we suggest that inactivation of infectious virus is not the only protective mechanism in this model.

PMID: 2838428 [PubMed - indexed for MEDLINE]



Entrez PubMed Overview Help | FAQ Tutorial New/Noteworthy E-Utilities

PubMed Services
Journals Database
MeSH Database
Single Citation Matcher
Batch Citation Matcher
Clinical Queries
Special Queries
LinkOut
My NCBI (Cubby)

Related Resources
Order Documents
NLM Catalog
NLM Galeway
TOXNET
Consumer Health
Clinical Alerts
ClinicalTrials.gov
PubMed Central

Passive immunization protects the mouse eye from damage after herpes simplex virus infection by limiting spread of virus in the nervous system.


Shimeld C, Hill TJ, Blyth WA, Easty DL.

Department of Ophthalmology, Medical School, University Walk, Bristol, U.K.

Mice were treated with serum containing antibodies to herpes simplex virus type 1 (HSV-1) or normal serum, 1 day before inoculation on the cornea with HSV-1 strain McKrae. As expected, without passive immunization, mice developed high levels of serum neutralizing antibody. By contrast, in passively immunized animals, such antibody became undetectable by 29 days after inoculation of serum, in spite of the virus infection. There was no difference between passively immunized mice and those given normal serum in the duration of shedding of virus in tears and the duration and severity of corneal epithelial disease. However, non-immunized mice had a high incidence of mortality and developed disease of the iris, corneal stroma and lids, and their comeas became opaque and vascularized. In nonimmunized animals, the timing of isolation of virus from nervous tissues and the sequence of appearance of virus antigens in ocular tissues indicate that the disease of deeper eye tissue was caused by virus spreading from the nervous system back to the eye. Restriction of such spread in passively immunized animals seems the likely explanation for their protection from death and severe ocular damage. Despite this restricted spread, passively immunized animals had a high incidence of latent infection in the ophthalmic part of the trigeminal ganglion. However, in comparison with mice given normal serum, there was a far lower incidence of such infection in the other two parts of this ganglion and in the superior cervical ganglion. Since passively immunized animals have a high incidence of latent infection in the ophthalmic part of the trigeminal ganglion and their eyes are normal, they will prove useful in studies involving induction of recurrent disease.

PMID: 2156001 [PubMed - indexed for MEDLINE]

Entrez PubMed Page 1 of 2



Entrez PubMed Overview Heip | FAQ Tutorial New/Noteworthy E-Utilities

PubMed Services
Journals Database
MeSH Database
Single Citation Matcher
Batch Citation Matcher
Clinical Queries
Special Queries
LinkOut
My NCBI (Cubby)

Related Resources
Order Documents
NLM Catalog
NLM Gateway
TOXNET
Consumer Health
Clinical Alerts
ClinicalTrials.gov
PubMed Central


Prophylactic and therapeutic effects of human immunoglobulin on the pathobiology of HSV-1 infection, latency, and reactivation in mice.

Dalai SK, Pesnicak L, Miller GF, Straus SE.

Medical Virology Section, Laboratory of Clinical Investigation, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, USA.

Pooled human immunoglobulin (IgG) was evaluated as prophylaxis and treatment of HSV-1 infection in mice. We compared the effects of IgG on the course of acute infection and spread of virus through the nervous system, as well as on the establishment, maintenance, and reactivation of virus from latency. Balb/c mice received a single 3.75 mg intraperitoneal injection of IgG 24 h before or 24 h, 48 h, or 72 h after ocular infection with 10(6) pfu of HSV-1 strain McKrae. Treatment with IgG protected against death in a time-dependent manner (P < 0.001 for -24 h vs. +48 h and +72 h IgG treatment groups). Viral shedding from the eyes was reduced more in mice treated with IgG at -24 h or +24 h relative to animals treated at +48 h. Viral titers in the eyes were reduced in mice treated with IgG at +24 h, but not at +48 h. In ganglia, virus recovery was reduced (P < 0.05) in mice treated at -24 h, +24 h, or +48 h relative to untreated mice, or ones treated at +72 h. In brains, similar results were observed in mice treated at -24 h, +24 h, or +48 h relative to +72 h. Upon explantation, virus reactivated from all ganglia of all surviving mice regardless of treatment group. DNA quantitation showed that mice pretreated with IgG tended towards lower quantities of latent genome copies compared to +24 h treatment and +48 h treatment. UV irradiation induced reactivation in vivo in 16/40 pretreated mice, 20/29 mice treated at +24 h, and in 8/8 mice treated at +48 h (P = 0.03 and P = 0.004, for comparisons at -24 h vs. +24 h, and -24 h vs. +48 h, respectively). Histopathological studies revealed that mice pretreated and treated with IgG had milder encephalitis and reduced virus spread compared to untreated mice. Pooled human IgG attenuates the spread of, and morbidity from, HSV-1 if given before and within 2 days after ocular infection.

Entrez PubMed Page 1 of 3



PMID: 6290850 [PubMed - indexed for MEDLINE]

6: Dix RD, Pereira L. Baringer JR.

Related Articles, Links

Use of monoclonal antibody directed against herpes simplex virus glycoproteins to protect mice against acute virus-induced neurological disease.

Infect Immun. 1981 Oct;34(1):192-9. PMID: 6271681 [PubMed - indexed for MEDLINE]

7: Chan WL, Lukig ML, Liew FY.

Related Articles, Links

Helper T cells induced by an immunopurified herpes simplex virus type I

Entrez PubMed Page 2 of 3



(HSV-I) 115 kilodalton glycoprotein (gB) protect mice against HSV-I infection.

J Exp Med. 1985 Oct 1;162(4):1304-18.

PMID: 2995536 [PubMed - indexed for MEDLINE]

8: Kohl S, Loo LS.

Related Articles, Links



Protection of neonatal mice against herpes simplex virus infection: probable in vivo antibody-dependent cellular cytotoxicity.

J Immunol. 1982 Jul;129(1):370-6.

PMID: 6282968 [PubMed - indexed for MEDLINE]

9: Morrison LA, Knipe DM.

Related Articles, Links



Immunization with replication-defective mutants of herpes simplex virus type 1: sites of immune intervention in pathogenesis of challenge virus infection.

J Virol. 1994 Feb;68(2):689-96.

PMID: 8289372 [PubMed - indexed for MEDLINE]

10: Oakes JE, Lausch RN.

Related Articles, Links



Role of Fc fragments in antibody-mediated recovery from ocular and subcutaneous herpes simplex virus infections.

Infect Immun. 1981 Jul;33(1):109-14.

PMID: 6266961 [PubMed - indexed for MEDLINE]

11: Kumel G, Kaerner HC, Levine M, Schroder CH, Glorioso JC. Related Articles, Links



Passive immune protection by herpes simplex virus-specific monoclonal antibodies and monoclonal antibody-resistant mutants altered in pathogenicity.

J Virol. 1985 Dec;56(3):930-7.

PMID: 2415719 [PubMed - indexed for MEDLINE]

12: Roberts PL, Duncan BE, Raybould TJ, Watson DH.

Related Articles, Links



Purification of herpes simplex virus glycoproteins B and C using monoclonal antibodies and their ability to protect mice against lethal challenge.

J Gen Virol. 1985 May;66 (Pt 5):1073-85.

PMID: 2582080 [PubMed - indexed for MEDLINE]

13: Mannini-Palenzona A. Costanzo F, Cassai E, Campana G.

Related Articles, Links



Passive immune protection by herpes simplex virus-specific monoclonal antibodies with different plaque development inhibition activity.

New Microbiol. 1993 Jul;16(3):205-13.

PMID: 8396193 [PubMed - indexed for MEDLINE]

14: Morrison LA, Zhu L, Thebeau LG.

Related Articles, Links



Vaccine-induced serum immunoglobin contributes to protection from herpes simplex virus type 2 genital infection in the presence of immune T cells.

J Virol. 2001 Feb;75(3):1195-204.

PMID: 11152492 [PubMed - indexed for MEDLINE]

15: Kitces EN, Morahan PS, Tew JG, Murray BK.

Related Articles, Links



Protection from oral herpes simplex virus infection by a nucleic acid-free

virus vaccine.

Infect Immun. 1977 Jun;16(3):955-60.

PMID: 197013 [PubMed - indexed for MEDLINE]

16: Sekizawa T. Openshaw H.

Related Articles, Links



Encephalitis resulting from reactivation of latent herpes simplex virus in mice.

J Virol. 1984 Apr;50(1):263-6.

PMID: 6321795 [PubMed - indexed for MEDLINE]

17: Kumano Y, Yamamoto M, Mori R.

Related Articles, Links



Protection against herpes simplex virus infection in mice by recombinant murine interferon-beta in combination with antibody.

Antiviral Res. 1987 Jun;7(5):289-301.

PMID: 2821897 [PubMed - indexed for MEDLINE]

18: Rooney JF, Wohlenberg C, Cremer KJ, Moss B, Notkins AL.

Related Articles, Links



Immunization with a vaccinia virus recombinant expressing herpes simplex virus type 1 glycoprotein D: long-term protection and effect of revaccination.

J Virol. 1988 May;62(5):1530-4.

PMID: 2833606 [PubMed - indexed for MEDLINE]

19: Ritchie MH, Oakes JE, Lausch RN.

Related Articles, Links



Passive transfer of anti-herpes simplex virus type 2 monoclonal and polyclonal antibodies protect against herpes simplex virus type 1-induced but not herpes simplex virus type 2-induced stromal keratitis.

Invest Ophthalmol Vis Sci. 1993 Jul;34(8):2460-8.

PMID: 8392037 [PubMed - indexed for MEDLINE]

20: Minagawa H, Sakuma S, Mohri S, Mori R, Watanabe T.

Related Articles, Links



Herpes simplex virus type 1 infection in mice with severe combined immunodeficiency (SCID).

Arch Virol. 1988;103(1-2):73-82.

PMID: 2850780 [PubMed - indexed for MEDLINE]

Items 1 - 20 of 142

Page 1 of 8 Next

Display Summary Show 20

NCBI | NLM | NIH

Department of Health & Human Services

Privacy Statement | Freedom of Information Act | Disclaimer

Write to the Help Desk

Sort by

Jun 1 2005 06:58:50

Record List Display Page 1 of 5

Hit List

Clear Generate Collection Print Fwd Refs Bkwd Refs
Generate OACS

Search Results - Record(s) 11 through 20 of 21 returned.

11. Document ID: US 6087188 A

L13: Entry 11 of 21 File: USPT Jul 11, 2000

US-PAT-NO: 6087188

DOCUMENT-IDENTIFIER: US 6087188 A

TITLE: Two-site immunoassay for an antibody with chemiluminescent label and biotin

bound ligand

DATE-ISSUED: July 11, 2000

INVENTOR-INFORMATION:

NAME CITY STATE ZIP CODE COUNTRY

Johansen; Niels Aller.o slashed.d DK

Ipsen; Hans-Henrik Hiller.o slashed.d DK

US-CL-CURRENT: $\frac{436}{526}$; $\frac{435}{174}$, $\frac{435}{181}$, $\frac{435}{7.1}$, $\frac{435}{7.5}$, $\frac{435}{7.5}$, $\frac{435}{7.92}$, $\frac{435}{7.95}$, $\frac{435}{971}$, $\frac{436}{507}$, $\frac{436}{512}$, $\frac{436}{513}$, $\frac{436}{518}$, $\frac{436}{523}$, $\frac{436}{524}$, $\frac{436}{525}$, $\frac{436}{532}$, $\frac{436}{538}$, $\frac{436}{547}$, $\frac{436}{548}$, $\frac{436}{811}$, $\frac{436}{821}$, $\frac{436}{824}$

12. Document ID: US 6075128 A

L13: Entry 12 of 21 File: USPT Jun 13, 2000

US-PAT-NO: 6075128

DOCUMENT-IDENTIFIER: US 6075128 A

** See image for <u>Certificate of Correction</u> **

TITLE: Materials and methods for isolating IgA immunoglobulins

DATE-ISSUED: June 13, 2000

INVENTOR-INFORMATION:

NAME CITY STATE ZIP CODE COUNTRY

Faulmann; Ervin Holland OH

US-CL-CURRENT: <u>530/413</u>; <u>530/412</u>

13. Document ID: US 5922845 A

L13: Entry 13 of 21

File: USPT

Jul 13, 1999

US-PAT-NO: 5922845

DOCUMENT-IDENTIFIER: US 5922845 A

TITLE: Therapeutic multispecific compounds comprised of anti-Fc.alpha. receptor

antibodies

DATE-ISSUED: July 13, 1999

INVENTOR-INFORMATION:

NAME CITY STATE ZIP CODE COUNTRY

Deo; Yashwant M. Audubon PA Graziano; Robert Frenchtown NJ Keler; Tibor Ottsville PA

US-CL-CURRENT: 530/387.3; 424/136.1, 424/184.1, 424/204.1, 424/234.1, 424/265.1,

 $\underline{424}/\underline{274.1}$, $\underline{424}/\underline{277.1}$, $\underline{435}/\underline{69.7}$, $\underline{530}/\underline{388.1}$, $\underline{530}/\underline{395}$, $\underline{536}/\underline{23.5}$

Full	Title	Citation	Front	Review	Classification	Date	Reference		Claims	KOME	Draw, De

14. Document ID: US 5833984 A

L13: Entry 14 of 21 F.

File: USPT Nov 10, 1998

US-PAT-NO: 5833984

DOCUMENT-IDENTIFIER: US 5833984 A

TITLE: Composition and method for preventing and treating inflammation with

Immunoglobulin A

DATE-ISSUED: November 10, 1998

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Eibl; Martha	Vienna			AT
Wolf; Hermann	Vienna			AT
Mannhalter; Josef W.	Vienna			AT
Leibl; Heinz	Vienna			AT
Linnau; Yendra	Vienna			AT

US-CL-CURRENT: 424/130.1; 424/184.1, 530/387.1, 530/861, 530/868

Full Title	Citation	Front	Review	Classification	Date	Reference	Comment of the control of the contro	KARAC	Drawa 5
	-								

15. Document ID: US 5808000 A

Record List Display Page 3 of 5

L13: Entry 15 of 21 File: USPT Sep 15, 1998

US-PAT-NO: 5808000

DOCUMENT-IDENTIFIER: US 5808000 A

** See image for Certificate of Correction **

TITLE: Virus-safe monomeric human immunoglobulin A and methods for its production

DATE-ISSUED: September 15, 1998

INVENTOR-INFORMATION:

NAME CITY STATE ZIP CODE COUNTRY

Mannhalter; Josef W. Vienna AT
Leibl; Heinz Vienna AT
Eibl; Martha Vienna AT
Tomasits; Regine Vienna AT
Wolf; Hermann Vienna AT

US-CL-CURRENT: 530/387.1; 435/5, 436/513, 436/547, 530/389.1

Full Ti	lie Citation	Front Review	Classification [) ate Reference	Claims	KWWC Draws D
	.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,	~~~~~	*************	*******************************	 	
, , , , , , , , , , , , , , , , , , ,		. TD . T.I.O. A	C 4 4000 A			

16. Document ID: US 5644030 A

L13: Entry 16 of 21 File: USPT Jul 1, 1997

US-PAT-NO: 5644030

DOCUMENT-IDENTIFIER: US 5644030 A

** See image for <u>Certificate of Correction</u> **

TITLE: Gene and method for production of an IgA binding protein

DATE-ISSUED: July 1, 1997

INVENTOR-INFORMATION:

NAME CITY STATE ZIP CODE COUNTRY

Faulmann; Ervin Holland OH

US-CL-CURRENT: 530/350; 530/402

17. Document ID: US 5629146 A

L13: Entry 17 of 21 File: USPT May 13, 1997

US-PAT-NO: 5629146

DOCUMENT-IDENTIFIER: US 5629146 A

TITLE: Method for detection of human papillomavirus (HPV) for diagnostic purposes

Record List Display Page 4 of 5

DATE-ISSUED: May 13, 1997

INVENTOR-INFORMATION:

NAME CITY STATE ZIP CODE COUNTRY

Dillner; Joakim Stockholm SE
Dillner; Lena Stockholm SE

US-CL-CURRENT: 435/5; 435/7.92, 436/513, 436/518, 436/813

18. Document ID: US 5180810 A

L13: Entry 18 of 21 File: USPT Jan 19, 1993

US-PAT-NO: 5180810

DOCUMENT-IDENTIFIER: US 5180810 A

TITLE: Protein H capable of binding to IgG

DATE-ISSUED: January 19, 1993

INVENTOR-INFORMATION:

NAME CITY STATE ZIP CODE COUNTRY Gomi; Hideyuki Osaka JP Hozumi; Tatsunobu Toyonaka JΡ Hattori; Shizuo Kobe JΡ Tagawa; Chiaki Takatsuki JP Kishimoto; Fumitaka Kawanishi JΡ Bjorck; Lars Sodra Sandby SE

US-CL-CURRENT: 530/350; 435/69.1

Full Title Citation Front Review Classification Date Reference

19. Document ID: US 4945039 A

L13: Entry 19 of 21 File: USPT Jul 31, 1990

US-PAT-NO: 4945039

DOCUMENT-IDENTIFIER: US 4945039 A

TITLE: Standard materials for measurement of immune complexes and method for

measurement of immune complexes

DATE-ISSUED: July 31, 1990

INVENTOR-INFORMATION:

NAME CITY STATE ZIP CODE COUNTRY

Suzuki; Hideaki Koganei JP

Hosoda; Kenji

Kawagoe

JΡ

Kubota; Takaharu

Hino


JΡ

Fukumoto; Yuji

Hachioji

JP

US-CL-CURRENT: 435/7.92; 435/18, 435/188, 435/7.94, 436/501, 436/507, 436/512, <u>436/518, 436/821, 530/389.3, 530/391.1, 530/391.5, 530/861, 530/863, 530/866,</u> 530/868



US-PAT-NO: 4740456

DOCUMENT-IDENTIFIER: US 4740456 A

TITLE: Immunological methods for diagnosing neurocysticercosis

DATE-ISSUED: April 26, 1988

INVENTOR-INFORMATION:

NAME

CITY

STATE

ZIP CODE

COUNTRY

Apr 26, 1988

Kuhn; Raymond E.

Clemmons

NC

File: USPT

Estrada; John J.

Winston-Salem

NC

Grogl; Max

Silver Spring

MD

US-CL-CURRENT: 435/7.22; 430/395, 430/403, 430/413, 430/417, 435/975, 436/516, 436/543, 436/811, 530/855

Full Title Citation Front	Review Classification			Claims	KMAC Draw De
······································				••••••	
Clear Generate Coll	ection Print	Fwd Refs	Bkwd Refs	General	e OACS
					¬ 1
Terms			Documents		_
serum IgA and Igo	G.clm.	_		2	1

Display Format: CIT Change Format

Previous Page

Next Page

Go to Doc#

First Hit

Previous Doc

Next Doc

Go to Doc#

End of Result Set

Generate Collection

Print

L17: Entry 1 of 1

File: DWPI

Mar 10, 2005

DERWENT-ACC-NO: 2005-213005

DERWENT-WEEK: 200522

COPYRIGHT 2005 DERWENT INFORMATION LTD

TITLE: Treatment of herpes simplex virus infections and herpetic disease in mammals involves administration of a composition comprising immunoglobulin A or immunoglobulin G prepared from pooled human plasma

Completed Constant Const

INVENTOR: BETZ, U; RADTKE, K; RADTKE, P

PRIORITY-DATA: 2003US-0656781 (September 5, 2003)

	Search Selected Search ALL Clear							
PAT	ENT-FAMILY:							
	PUB-NO	PUB-DATE	LANGUAGE	PAGES	MAIN-IPC			
	US 20050053605 A1	March 10, 2005		011	A61K039/42			
	WO 2005023303 A1	March 17, 2005	E	000	A61K039/44			
	WO 2005025617 A2	March 24, 2005	E	000	A61K039/395			

INT-CL (IPC): A61 K 35/16; A61 K 39/395; A61 K 39/42; A61 K 39/44

ABSTRACTED-PUB-NO: US20050053605A

BASIC-ABSTRACT:

NOVELTY - Treatment or prophylaxis of herpes simplex virus infections or herpetic disease in mammals involves administration of a composition comprising immunoglobulin A (\underline{IgA}) or immunoglobulin G (\underline{IgG}) prepared from pooled human plasma. (\underline{IgA}) Is administered intravenously and (\underline{IgG}) is administered intravenously or topically.

ACTIVITY - Virucide; Antiinflammatory; Neuroprotective; Hepatotropic; Ophthalmological.

A group of mice were infected with HSV on the cornea of one eye and treated on the day of infection and on the 4 following days 3 times per day with human IgG, mIgA and dIgA or with placebo (phosphate buffered saline, PBS = 150 mM NaCl, 20 mM phosphate, pH 7 - 7.4). Seven days after infection, all animals treated only with placebo had developed ocular HSV disease in combination with a lethal HSV encephalitis, while 7 out of 10 animals treated with topical IgG 3 times per day had survived and showed no signs of ocular HSV-disease.

MECHANISM OF ACTION - None given.

USE - For the treatment of herpes simplex virus infection in mammal e.g. neonatal

human or immunocompromised mammal suffering from a herpetic disease, e.g. encephalitis, pneumonia, hepatitis, herpes ocularis, chickenpox, shingles, zoster oticus, zoster varicellosus, keratitis, herpes digitalis, herpes facialis, herpes genitalis, herpes gladiatorum, herpes stomatitis, ocular herpetic disease (claimed) and labialis; in medical therapy for the treatment of herpes viral infections including herpes simplex viruses type-1 and type-2 (HSV-1 and HSV-2), varicella zoster virus (VZV), cytomegalovirus (CMV), and Epstein-Barr virus (EBV).

ADVANTAGE - Due to topical administration of purified human IgG from pooled human plasma, no injection of immunoglobulin is necessary. Patients can treat themselves with topical IgG in an ophthalmic formulation. IgG from pooled human plasma is suitable for this purpose without a need for screening of blood donors based on their HSV-neutralizing antibody level.

ABSTRACTED-PUB-NO: US20050053605A

EQUIVALENT-ABSTRACTS:

CHOSEN-DRAWING: Dwg.0/4

Previous Doc Next Doc Go to Doc#

WEST Search History

:	***************************************	***************************************	***************************************
Hide Items	Doctoro	Classi	Concol
STHUE REINS ST	**************************************	······································	······································
	***************************************	***************************************	***************************************

DATE: Tuesday, June 07, 2005

Hide?	Set Nam	<u>e Query</u>	Hit Count
	DB=PC	GPB; PLUR=YES; OP=ADJ	
	L19	Betz .in. and IgA	1
	DB=US	SPT; PLUR=YES; OP=ADJ	
	L18	Betz .in. and IgA	0
	DB=DV	WPI; PLUR=YES; OP=ADJ	
	L17	Betz U.in. and IgA	1
	L16	Betz U.in.	52
	L15	Btz U.in.	0
	L14	serum IgA and IgG	10
	DB=US	SPT; PLUR=YES; OP=ADJ	
	L13	serum IgA and IgG.clm.	21
	L12	pooled serum IgA and IgG.clm.	0
	L11	serum IgA and HSV.clm.	1
	L10	serum IgG and HSV.clm.	2
	L9	IgG adj HSV.clm.	0
\Box	L8	IgG antibodies adj HSV.clm.	0
	L7	Roizman Bernard.in.	26
	L6	IgG antibodies and HSV.clm.	35
	L5	IgA antibodies and HSV.clm.	4
	L4	pooled antibodies .clm.	0
	L3	pooled serum antibodies .clm.	0
	L2	pooled serum antibodies and herpesvirus.clm.	0
	L1	serum antibodies and herpesvirus.clm.	20

END OF SEARCH HISTORY